163 related articles for article (PubMed ID: 37860193)
1. Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.
Kiss Z; Gálffy G; Müller V; Moldvay J; Sárosi V; Pápai-Székely Z; Csada E; Kerpel-Fronius A; Király Z; Szász Z; Hódi G; Polányi Z; Kovács K; Karamousouli E; Knollmajer K; Szabó TG; Berta A; Vokó Z; Rokszin G; Abonyi-Tóth Z; Barcza Z; Tamási L; Bogos K
Front Oncol; 2023; 13():1207295. PubMed ID: 37860193
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
3. Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From Hungary.
Kiss Z; Bogos K; Tamási L; Ostoros G; Müller V; Urbán L; Bittner N; Sárosi V; Vastag A; Polányi Z; Nagy-Erdei Z; Knollmajer K; Várnai M; Nagy B; Horváth K; Rokszin G; Abonyi-Tóth Z; Barcza Z; Moldvay J; Gálffy G; Vokó Z
Pathol Oncol Res; 2021; 27():1610041. PubMed ID: 35002544
[No Abstract] [Full Text] [Related]
4. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
[TBL] [Abstract][Full Text] [Related]
5. Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011-2016.
Bogos K; Kiss Z; Tamási L; Ostoros G; Müller V; Urbán L; Bittner N; Sárosi V; Vastag A; Polányi Z; Nagy-Erdei Z; Daniel A; Vokó Z; Nagy B; Horváth K; Rokszin G; Abonyi-Tóth Z; Barcza Z; Gálffy G; Moldvay J
Pathol Oncol Res; 2021; 27():603937. PubMed ID: 34257563
[No Abstract] [Full Text] [Related]
6. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Waterhouse D; Lam J; Betts KA; Yin L; Gao S; Yuan Y; Hartman J; Rao S; Lubinga S; Stenehjem D
Lung Cancer; 2021 Jun; 156():41-49. PubMed ID: 33894493
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe.
Hofmarcher T; Lindgren P; Wilking N
J Cancer Policy; 2022 Dec; 34():100362. PubMed ID: 36087918
[TBL] [Abstract][Full Text] [Related]
9. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
10. Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.
Carroll NM; Eisenstein J; Burnett-Hartman AN; Greenlee RT; Honda SA; Neslund-Dudas CM; Rendle KA; Vachani A; Ritzwoller DP
Cancer Treat Res Commun; 2023; 36():100730. PubMed ID: 37352588
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
13. Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative.
Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Manley Daumont M; Penrod JR; O'Donnell JC; Hall G
BMJ Open; 2021 May; 11(5):e043442. PubMed ID: 33941627
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
[TBL] [Abstract][Full Text] [Related]
15. Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung.
Hsiao SH; Chen WT; Chung CL; Chou YT; Lin SE; Hong SY; Chang JH; Chang TH; Chien LN
Cancer Med; 2022 May; 11(10):2067-2078. PubMed ID: 35274494
[TBL] [Abstract][Full Text] [Related]
16. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
[TBL] [Abstract][Full Text] [Related]
17. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
18. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
19. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.
Tiu AC; Potdar R; Djibo DA; Masab M; Dourado C
Med Oncol; 2018 Jun; 35(7):109. PubMed ID: 29915891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
